Blood Coagulation & Fibrinolysis最新文献_第10页

Disseminated intravascular coagulation in acute leukemia patients. 急性白血病患者弥散性血管内凝血。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001245

Tomoyuki Kawada

引用次数: 0

Measuring coagulopathy in pediatric craniofacial surgery. 测量小儿颅面外科的凝血功能。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001234

Alexandra J Borst, Christopher M Bonfield, Poornachanda S Deenadayalan, Chi H Le, Meng Xu, Srijaya K Reddy

{"title":"Measuring coagulopathy in pediatric craniofacial surgery.","authors":"Alexandra J Borst, Christopher M Bonfield, Poornachanda S Deenadayalan, Chi H Le, Meng Xu, Srijaya K Reddy","doi":"10.1097/MBC.0000000000001234","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001234","url":null,"abstract":"The goal of this study was to describe hematologic and coagulation laboratory parameters and identify if these laboratory studies could predict blood loss in a cohort of pediatric patients undergoing complex cranial vault reconstruction (CCVR) for repair of craniosynostosis. We reviewed records from 95 pediatric CCVR patients between 2015 and 2019. Primary outcome measures were hematologic and coagulation laboratory parameters. Secondary outcome measures were intraoperative and postoperative calculated blood loss (CBL). Preoperative laboratory values were within normal limits and did not predict outcomes. Intraoperative platelet count and fibrinogen predicted CBL but without clinically relevant thrombocytopenia or hypofibrinogenemia. Intraoperative prothrombin time (PT) and partial thromboplastin time (PTT) predicted perioperative CBL, possibly reflecting surgically induced coagulopathy. Postoperative laboratory values did not predict postoperative blood loss. We found that standard hematologic and coagulation laboratory parameters predicted intraoperative and postoperative blood loss but provided limited mechanistic information to improve our understanding of coagulopathy in craniofacial surgery.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens. 阿哌沙班与利伐沙班在三联抗血栓治疗方案中出血和缺血事件的比较。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001238

Maya R Chilbert, Ashley E Woodruff, Marissa Saber, Pavel Goriacko, Mark Sinnet, David Jacobs

{"title":"Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens.","authors":"Maya R Chilbert, Ashley E Woodruff, Marissa Saber, Pavel Goriacko, Mark Sinnet, David Jacobs","doi":"10.1097/MBC.0000000000001238","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001238","url":null,"abstract":"Objective: To compare the risk of readmissions for major bleeding within one year between apixaban and rivaroxaban as a component of triple antithrombotic therapy.Methods: This study was a multicenter, retrospective cohort study conducted at two academic medical centers in the Western New York and New York City region between July 1, 2011 and September 25, 2019. Adult patients were included if they were diagnosed with atrial fibrillation or venous thromboembolism and discharged on new triple antithrombotic therapy. The primary outcome compared the rates of 1-year readmission for major bleeding between apixaban and rivaroxaban groups. Secondary outcomes included rate of ischemic outcomes. Time to event analysis was determined with a Kaplan-Meier plot and Cox proportional hazard ratios (HR).Results: A total of 378 patients were included in the study, 212 in the apixaban group and 166 in the rivaroxaban group. Within 1 year, readmission for major bleeding events occurred in six (2.8%) patients in the apixaban group and four (2.4%) patients in the rivaroxaban group ( P = 1.000). After adjustment, the major bleeding event rate was not statistically significantly different between apixaban and rivaroxaban [adjusted hazard ratio (aHR) 0.68, 95% confidence interval (CI) 0.12-3.77; P = 0.6624]. Higher albumin levels were identified to be protective against major bleeding related readmission events (aHR 0.18, 95% CI 0.05-0.63; P = 0.0072). The ischemic outcome occurred in seven (3.3%) patients in the apixaban group and three (1.8%) in the rivaroxaban group ( P = 0.7368).Conclusion: Use of apixaban or rivaroxaban in a triple antithrombotic regimen was not associated with bleeding or ischemic outcomes.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of factor XII deficiency in critically ill patients with a prolonged activated partial thromboplastin time: a prospective observational study. 激活部分凝血活酶时间延长的危重患者中因子XII缺乏的发生率:一项前瞻性观察研究。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001235

Lipi Mishra, David Lee, Kwok M Ho

{"title":"Incidence of factor XII deficiency in critically ill patients with a prolonged activated partial thromboplastin time: a prospective observational study.","authors":"Lipi Mishra, David Lee, Kwok M Ho","doi":"10.1097/MBC.0000000000001235","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001235","url":null,"abstract":"Limited data is available on factor XII deficiency in critically ill patients with prolonged activated partial thromboplastin time (aPTT). The association of factor XII deficiency with an increased risk of thromboembolism is unclear. This prospective observational study assessed the incidence of factor XII deficiency among critically ill patients with prolonged aPTT (>40 s), whether factor XII deficiency manifesting as prolonged aPTT was associated with an increased risk of thromboembolism, and clotting time on a viscoelastic (ROTEM) test was useful to predict factor XII deficiency. Of the 40 included patients, 48% [95% confidence interval (CI) 33-63) had a factor XII deficiency (mean ± standard deviation of factor XII level of all patients: 54% ± 29%). Factor XII levels were not significantly correlated with the measured aPTT ( r = -0.163, P = 0.315). Factor XII deficiency was significantly more common in patients who were less critically ill ( P = 0.027), but it was not significantly related to Disseminated Intravascular Coagulation scores ( P = 0.567). The incidence of symptomatic venous thromboembolism ( P = 0.246), allogeneic blood transfusion ( P = 0.816), and hospital mortality ( P = 0.201) were not significantly different between those with and without factor XII deficiency. The clotting time on the viscoelastic test was not predictive of factor XII deficiency (area under the receiver-operating characteristic = 0.605, P = 0.264). Factor XII deficiency was common in critically ill patients with a prolonged aPTT. There was no association between factor XII deficiency and risk of thromboembolism. The clotting time on ROTEM was not predictive of the presence of factor XII deficiency.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A. 重组VIIa因子与血浆源性VIIa因子及X因子联合治疗获得性血友病A难治性出血的安全性。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001243

Yusuke Okayama, Masato Bingo, Kazuki Sakatoku, Hiroshi Okamura, Satoru Nanno, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae

{"title":"The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A.","authors":"Yusuke Okayama, Masato Bingo, Kazuki Sakatoku, Hiroshi Okamura, Satoru Nanno, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae","doi":"10.1097/MBC.0000000000001243","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001243","url":null,"abstract":"Acquired hemophilia A (AHA) is a rare, life-threatening hemorrhagic disease caused by autoantibodies against factor VIII (FVIII), and bypassing agents (BPA) are used to control bleeding. However, some cases need a change of BPA or BPAs given sequentially or in combination for refractory bleeding. A 71-year-old man was admitted with subcutaneous hemorrhage. Laboratory investigations showed prolongation of activated partial thromboplastin time (APTT) and low-coagulation FVIII activity and FVIII inhibitor; we, therefore, diagnosed AHA. He was treated with recombinant factor VIIa (rFVIIa) BPA and prednisolone. However, his symptoms did not improve sufficiently, thus we switched BPA to activated prothrombin complex concentrate. Unfortunately, this was not effective and he suffered hemorrhagic shock. Therefore, we selected rFVIIa, with plasma-derived FVIIa and factor X (pd-FVIIa/FX) as combination therapy, and hemostasis was achieved without thrombosis. This case suggests that the combination of rFVIIa and pd-FVIIa/FX short-term can be well tolerated for refractory hemorrhage in AHA.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10016649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Sinopharm vaccine in patients with congenital bleeding disorders under on-demand therapy: a preliminary report. 国药集团疫苗在按需治疗先天性出血性疾病患者中的安全性:初步报告。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001227

Amin Shahsavani, Sezaneh Haghpanah, Tahereh Zarei, Asghar Bazrafshan, Mehran Karimi

引用次数: 0

Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients. 静脉血栓栓塞和急性髓性白血病:老年白人、黑人和亚洲患者的危险因素和死亡率。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-09-01 DOI: 10.1097/MBC.0000000000001226

Ambarina S Faiz, Shuang Guo, Ashwin Sridharan, Yong Lin, Claire S Philipp

{"title":"Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients.","authors":"Ambarina S Faiz, Shuang Guo, Ashwin Sridharan, Yong Lin, Claire S Philipp","doi":"10.1097/MBC.0000000000001226","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001226","url":null,"abstract":"Risk factors for venous thromboembolism (VTE) in elderly patients with acute myeloid leukemia (AML) are not known by race. The aim of this study was to determine the association of VTE with known risk factors and the impact of VTE on mortality in elderly white, black and Asian patients with AML. The merged SEER-Medicare database (2000-2015) was used for patients aged at least 65 years diagnosed with AML. Multivariable logistic regression was used to examine the association of VTE with known risk factors and Cox proportional hazards regression was used to evaluate the association of VTE with mortality in white, black and Asian patients. Among 21 403 AML patients aged at least 65years, VTE was diagnosed in 10.6% of 18 731 white patients, 13.4% of 1362 black and 5.6% of 1310 Asian patients. Overall, the adjusted risk of VTE in black patients was similar to white patients, but Asian patients had a lower risk of VTE. Risk factors for VTE in white patients were age less than 75 years, female sex, chemotherapy and comorbid medical conditions, including hypertension, anemia, chronic kidney and lung disease, hyperlipidemia, heart failure and obesity. In black patients, hyperlipidemia, and heart failure and in Asian patients, age less than 75 years, female sex, chemotherapy and hypertension and myocardial infarction were associated with VTE. Central venous catheter placement was a predictor of VTE in all three races. Our study identified risk factors for VTE by race in elderly white, black and Asian AML patients.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen. 纤维蛋白原不良血症：输注纯化纤维蛋白原后的结果不一致。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-07-01 Epub Date: 2023-06-19 DOI: 10.1097/MBC.0000000000001237

Maximo J Marin, Carol M Mathew, Anita Rajasekhar, Marc Zumberg, Tammy Y Euliano, William E Winter, J Peter R Pelletier, Heather D Pruitt, Neil S Harris

{"title":"Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen.","authors":"Maximo J Marin, Carol M Mathew, Anita Rajasekhar, Marc Zumberg, Tammy Y Euliano, William E Winter, J Peter R Pelletier, Heather D Pruitt, Neil S Harris","doi":"10.1097/MBC.0000000000001237","DOIUrl":"10.1097/MBC.0000000000001237","url":null,"abstract":"Inherited dysfibrinogenemias are molecular disorders of fibrinogen that affect fibrin polymerization. The majority of cases are asymptomatic, but a significant proportion suffer from increased bleeding or thrombosis. We present two unrelated cases of dysfibrinogenemia, both of whom showed a characteristic discrepancy between fibrinogen activity and the immunologic fibrinogen. In one patient, the dysfibrinogenemia was confirmed by molecular analysis; in the other case, the diagnosis was presumptive based upon laboratory studies. Both patients underwent elective surgery. Both received a highly purified fibrinogen concentrate preoperatively and demonstrated a suboptimal laboratory response to the infusion. Three methods for determining fibrinogen concentration (Clauss fibrinogen, prothrombin-derived fibrinogen, and the viscoelastic functional fibrinogen) were utilized in the case of one patient, and these techniques showed discrepant results with the classic Clauss method giving the lowest concentration. Neither patient experienced excessive bleeding during surgery. Although these discrepancies have been previously described in untreated patients, their manifestation after infusion of purified fibrinogen is less well appreciated.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10177617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resolution of cardiac surgical bleeding with the combination of 4-factor prothrombin complex concentrate and fresh frozen plasma following lack of response to fresh frozen plasma alone in a patient with severe factor XI deficiency. 一名严重因子 XI 缺乏症患者在单用新鲜冰冻血浆无效后，联合使用 4 因子凝血酶原复合物浓缩物和新鲜冰冻血浆，解决了心脏手术出血问题。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-07-01 Epub Date: 2023-06-21 DOI: 10.1097/MBC.0000000000001236

Percy Boateng, Mala Varma, Lilyanne Chen, Hein Kyaw, Nay Lin Kyaw, Joseph Yoe

引用次数: 0

Fibrinolytic drugs induced hemorrhage: mechanisms and solutions. 纤溶药物诱发出血：机制与解决方案。

IF 1.1 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2023-07-01 Epub Date: 2023-06-06 DOI: 10.1097/MBC.0000000000001231

Mingqing Tang, Chengjia Hu, Hongjun Lin, Hui Yan

引用次数: 0